Clinical Trial Update: Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

View source ↗

Summary

PRISMM evaluates immunotherapy guided by spliceosome mutational markers in patients with metastatic solid tumors carrying SF3B1, U2AF1, or SRSF2 mutations. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Metastatic Solid Tumor, SF3B1 Gene Mutation | Status: ACTIVE_NOT_RECRUITING